- Appointed Dr. Mark A. Klausner as Chief Medical Officer;
- Announced interim results and clinical update for Phase II study of CRMD001 (a proprietary formulation of deferiprone);
Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate
Biotech columnist Adam Feuerstein answers readers' questions about health care.
CorMedix (CRMD) shares are rising after the company said that the FDA gave positive feedback for its catheter lock solution for oncology patients.